MMP1 and hydrops fetalis: already demonstrated the potential of CITP:MMP1 assessment regarding the favorable effects through spironolactone treatment in (i) HF patients with preserved EF (HFpEF) (Aldo‐DHF trial) and (ii) patients at risk of HF (HOMAGE trial).4, 5